ABCD debate at the annual ABCD virtual meeting 18 December 2020

Authors

  • Dinesh Kumar Nagi Edna Coates Diabetes and Endocrine Unit, Pinderfields Hospital, Mid Yorkshire NHS Trust Wakefield
  • Umesh Dashora

DOI:

https://doi.org/10.15277/bjd.2021.330

Abstract

Speakers: 

For the Motion: Dr Stephen Wheatcroft, Consultant Cardiologist and Professor of Cardiometabolic Medicine, University of Leeds, West Yorkshire

Against the Motion: Professor John Wilding. Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, Clinical Sciences Centre, Aintree University Hospital, Liverpool

Author Biography

Dinesh Kumar Nagi, Edna Coates Diabetes and Endocrine Unit, Pinderfields Hospital, Mid Yorkshire NHS Trust Wakefield

Honorary Consultant in Diabetes & Endocrinology

References

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720

Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–57. https://doi.org/10.1056/NEJMoa1611925

Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS program randomised clinical trials. Lancet Diabetes Endocrinol 2018;6(9):691–704. https://doi.org/10.1016/S2213-8587(18)30141-4

Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380(4): 347–57. https://doi.org/10.1056/NEJMoa1812389

Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020;383: 1425–35. https://doi.org/10.1056/NEJMoa2004967

Heerspink H, Stefansson B, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383: 1436–46. https://doi.org/10.1056/NEJMoa2024816

McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995–2008. https://doi.org/10.1056/NEJMoa1911303

Packer M, Anker S, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383: 1413–24. https://doi.org/10.1056/NEJMoa2022190

Summary of Product Characteristics. Forxiga 5 mg and 10 mg film coated tablets. www.medicines.org.uk/emc/product/2865/smpc

Dashora U, Gallagher A, Dhatariya K, Winocour P, Gregory R, ABCD Committee. Association of British Clinical Diabetologists (ABCD) position statement on the risk of diabetic ketoacidosis associated with the use of sodium-glucose cotransporter-2 inhibitors. Br J Diabetes 2016;16(4):206–9. http://dx.doi.org/10.15277/bjd.2016.112

Dashora U, on behalf of CaReMe UK. Manage diabetes and comorbidities with a joined-up strategy. May 2021. https://www.guidelinesinpractice.co.uk/diabetes/manage-diabetes-and-comorbidities-with-a-joined-up-strategy/456004.article

Dashora U, Gregory R, Winocour P, et al. Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes. Clin Med 2021;21(3):204–10. https://doi.org/10.7861/clinmed.2021-0045

Downloads

Published

2021-12-17

Issue

Section

Meeting Reports